#China #Beijing #Synthetic Biology #Tsingke Biotech #iGeneTech

Tsingke Biotech and iGeneTech Collaborate for a Revolutionary Leap in Synthetic Biology

In a significant move toward innovation within the field of synthetic biology, Beijing Tsingke Biotech Co., Ltd. has officially teamed up with iGeneTech Bioscience Co., Ltd. This strategic partnership, announced on March 10, 2026, marks a union of expertise that aims not only to push forward their product development but also to respond to the escalating demands of the market.

A Collaborative Vision

The formalization of this partnership took center stage during a signing ceremony at Tsingke Biotech’s headquarters in Beijing. Leaders from both companies conveyed their mutual dedication to pioneering advancements in synthetic biology. The burgeoning field is recognized for its potential application across various sectors, including precision medicine, bio-breeding, and gene editing. By combining their forces, Tsingke Biotech and iGeneTech plan to effectively address these market needs.

Tsingke Biotech's Advanced Capabilities

Tsingke Biotech has established a dominant position in gene synthesis, developing a fully integrated industrial chain that includes raw materials, production equipment, and AI-driven digital technologies. The company's remarkable technological framework includes:

• - Column Synthesis: Streamlined methods for gene synthesis that enhances both speed and reliability.
• - Scalable Production: Capabilities that range from small-scale laboratory production to large-scale industrial synthesis, which can accommodate varying sizes to serve different R&D needs.

Their suite of services encompasses:

• - Primer Synthesis (< 300 nt)
• - Gene Synthesis (300 bp – 5 kb)
• - Long Gene Synthesis (> 5 kb)

iGeneTech's Innovative Approach

On the other hand, iGeneTech enhances this partnership with its proprietary Ignite 3.0 platform, which distinguishes itself through:

• - High-throughput capabilities: Capable of processing oligo pools that range from 4,000 to 650,000 in size.
• - Precision: Achieves synthesis lengths of up to 200 nt with minimal error rates, leading to a significant reduction in costs and increased throughput efficiency.

By leveraging these cutting-edge technologies, both firms hope to address key challenges in the sector and drive the development of innovative solutions.

Leadership Perspectives

Shijin Ma, CEO of Tsingke Biotech, articulated the excitement surrounding the partnership: “We are thrilled to partner with iGeneTech. Their expertise in gene capture and next-generation sequencing complements our capabilities in gene synthesis. Together, we will translate technological advances into practical applications.”

Similarly, Wanshi Cai, CEO of iGeneTech, echoed this enthusiasm: “Tsingke Biotech's comprehensive industrial chain is integral to our growth. This partnership will help us redefine the capabilities of synthetic biology across various industries.”

A Shared Commitment to Innovation

The essence of this strategic alliance is not just about merging capabilities but also about creating a comprehensive system that encompasses every aspect of the synthetic biology process—from synthesis to application. The businesses are dedicated to harnessing innovation with sustainability at its core, positioning themselves to cater to a rapidly evolving market.

What Lies Ahead

This partnership stands as a testament to the potential of collaboration within the realm of synthetic biology. With both companies committed to excellence in innovation and precision, the future is promising. Tsingke Biotech’s ambition to become “the world’s great gene factory” aligns seamlessly with iGeneTech’s expertise in NGS technology, setting the stage for groundbreaking advancements.

In conclusion, the collaboration between Tsingke Biotech and iGeneTech opens new avenues not only for both companies but for the industry at large, aiming for a revolutionary leap in synthetic biology applications that can lead to improvements in health, agriculture, and environmental sustainability.